Multi-Omics Analysis Reveals the Attenuation of the Interferon Pathway as a Driver of Chemo-Refractory Ovarian Cancer
Abstract Ovarian high-grade serous carcinoma (HGSC) represents the deadliest gynecological malignancy, with 10-15% of patients exhibiting primary resistance to first-line chemotherapy. These primarily chemo-refractory patients have particularly poor survival outcomes, emphasizing the urgent need for developing predictive biomarkers and novel therapeutic approaches. Here, we show that interferon type I (IFN-I) pathway activity in cancer cells is a crucial determinant of chemotherapy response in HGSC. Through a comprehensive multi-omics analysis within the DECIDER observational trial (<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</jats:ext-link>identifier<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" xlink:href="NCT04846933">NCT04846933</jats:ext-link>) cohort, we identified that chemo-refractory HGSC is characterized by diminished IFN-I and enhanced hypoxia pathway activities. Importantly, IFN-I pathway activity was independently prognostic for patient survival, highlighting its potential as a biomarker. Our results elucidate the heterogeneity of treatment response at the molecular level and suggest that augmentation of IFN-I response could enhance chemosensitivity in refractory cases. This study underscores the potential of the IFN-I pathway as a therapeutic target and advocates for the initiation of clinical trials testing external modulators of the IFN-I response, promising a significant stride forward in the treatment of refractory HGSC..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 03. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Afenteva, Daria [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2024.03.28.587131 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI043102328 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI043102328 | ||
| 003 | DE-627 | ||
| 005 | 20240405120340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240331s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.03.28.587131 |2 doi | |
| 035 | |a (DE-627)XBI043102328 | ||
| 035 | |a (biorXiv)10.1101/2024.03.28.587131 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Afenteva, Daria |e verfasserin |0 (orcid)0009-0000-9596-2832 |4 aut | |
| 245 | 1 | 0 | |a Multi-Omics Analysis Reveals the Attenuation of the Interferon Pathway as a Driver of Chemo-Refractory Ovarian Cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Ovarian high-grade serous carcinoma (HGSC) represents the deadliest gynecological malignancy, with 10-15% of patients exhibiting primary resistance to first-line chemotherapy. These primarily chemo-refractory patients have particularly poor survival outcomes, emphasizing the urgent need for developing predictive biomarkers and novel therapeutic approaches. Here, we show that interferon type I (IFN-I) pathway activity in cancer cells is a crucial determinant of chemotherapy response in HGSC. Through a comprehensive multi-omics analysis within the DECIDER observational trial (<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</jats:ext-link>identifier<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" xlink:href="NCT04846933">NCT04846933</jats:ext-link>) cohort, we identified that chemo-refractory HGSC is characterized by diminished IFN-I and enhanced hypoxia pathway activities. Importantly, IFN-I pathway activity was independently prognostic for patient survival, highlighting its potential as a biomarker. Our results elucidate the heterogeneity of treatment response at the molecular level and suggest that augmentation of IFN-I response could enhance chemosensitivity in refractory cases. This study underscores the potential of the IFN-I pathway as a therapeutic target and advocates for the initiation of clinical trials testing external modulators of the IFN-I response, promising a significant stride forward in the treatment of refractory HGSC. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Yu, Rong |e verfasserin |0 (orcid)0000-0002-8488-0417 |4 aut | |
| 700 | 1 | |a Rajavuori, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Salvadores, Marina |e verfasserin |0 (orcid)0000-0002-7850-7691 |4 aut | |
| 700 | 1 | |a Launonen, Inga-Maria |e verfasserin |0 (orcid)0000-0002-4548-9650 |4 aut | |
| 700 | 1 | |a Lavikka, Kari |e verfasserin |0 (orcid)0000-0002-4163-4945 |4 aut | |
| 700 | 1 | |a Zhang, Kaiyang |e verfasserin |0 (orcid)0000-0002-0470-9581 |4 aut | |
| 700 | 1 | |a Marchi, Giovanni |e verfasserin |0 (orcid)0000-0001-9513-1123 |4 aut | |
| 700 | 1 | |a Jamalzadeh, Sanaz |e verfasserin |0 (orcid)0000-0002-6425-9455 |4 aut | |
| 700 | 1 | |a Isoviita, Veli-Matti |e verfasserin |0 (orcid)0000-0001-7329-8934 |4 aut | |
| 700 | 1 | |a Li, Yilin |e verfasserin |0 (orcid)0000-0002-3268-1969 |4 aut | |
| 700 | 1 | |a Micoli, Giulia |e verfasserin |0 (orcid)0009-0003-9541-8177 |4 aut | |
| 700 | 1 | |a Erkan, Erdogan Pekcan |e verfasserin |0 (orcid)0000-0001-9287-4773 |4 aut | |
| 700 | 1 | |a Falco, Matias M. |e verfasserin |0 (orcid)0000-0002-6813-0050 |4 aut | |
| 700 | 1 | |a Ungureanu, Daniela |e verfasserin |0 (orcid)0000-0002-9314-4972 |4 aut | |
| 700 | 1 | |a Lahtinen, Alexandra |e verfasserin |0 (orcid)0000-0001-7179-2680 |4 aut | |
| 700 | 1 | |a Oikkonen, Jaana |e verfasserin |0 (orcid)0000-0002-1063-2736 |4 aut | |
| 700 | 1 | |a Hietanen, Sakari |e verfasserin |0 (orcid)0000-0003-4734-4743 |4 aut | |
| 700 | 1 | |a Vähärautio, Anna |e verfasserin |0 (orcid)0000-0003-4721-3954 |4 aut | |
| 700 | 1 | |a Sur, Inderpreet |e verfasserin |0 (orcid)0000-0001-5787-1040 |4 aut | |
| 700 | 1 | |a Virtanen, Anni |e verfasserin |0 (orcid)0000-0002-7467-8434 |4 aut | |
| 700 | 1 | |a Färkkilä, Anniina |e verfasserin |0 (orcid)0000-0002-3558-6617 |4 aut | |
| 700 | 1 | |a Hynninen, Johanna |e verfasserin |0 (orcid)0000-0002-0854-7225 |4 aut | |
| 700 | 1 | |a Muranen, Taru A. |e verfasserin |0 (orcid)0000-0002-5895-1808 |4 aut | |
| 700 | 1 | |a Taipale, Jussi |e verfasserin |0 (orcid)0000-0003-4204-0951 |4 aut | |
| 700 | 1 | |a Hautaniemi, Sampsa |e verfasserin |0 (orcid)0000-0002-7749-2694 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 03. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:03 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.03.28.587131 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 03 |c 04 | ||